Non-Human Primate (NHP) Applications by Therapeutic Modalities

Are you currently facing complex challenges in developing advanced therapeutic modalities, such as unpredictable efficacy in human trials or regulatory hurdles for novel therapies? Creative Biolabs help you de-risk your development pipeline and accelerate the path to the clinic through our unparalleled expertise in NHP models. We provide a crucial translational bridge between laboratory research and human clinical trials, ensuring that your innovative therapies are safe and effective.

Navigating Complexity, Advancing Therapies with Our NHP Models.

NHPs provide a vital and irreplaceable preclinical platform for evaluating the safety, efficacy, and pharmacokinetics of novel therapeutic modalities.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Our research services are focused on supporting the development of advanced therapeutic modalities, providing a critical link between foundational research and clinical application. We specialize in areas where NHP models are indispensable for generating robust, translational data required for regulatory approval and successful human trials.

Gene Therapy: This field involves the use of therapeutic nucleic acids (DNA or RNA) to correct a defective gene or introduce a new one. NHPs are essential for evaluating vector biodistribution, shedding, and long-term expression profiles, ensuring the therapy reaches its intended target without causing off-target effects.
Cell Therapy (CAR-T, iPSC, MSC): Cell-based therapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, induced Pluripotent Stem Cells (iPSC), and Mesenchymal Stem Cells (MSC), are transforming medicine. NHPs are used to model the complex immune responses, such as cytokine release syndrome (CRS) and neurotoxicity, and to evaluate cell persistence, engraftment, and tumor-killing efficacy in a relevant physiological context.
Biologics & Complex Modalities: This category includes large-molecule drugs like monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. NHPs are ideal for assessing the pharmacokinetics, pharmacodynamics, and immunogenicity of these complex molecules, given their high translational relevance to human systems.
Vaccines & Infectious Disease: In the development of new vaccines and treatments for infectious diseases, NHPs are the gold standard. They can be used to model specific diseases, providing a platform to test vaccine efficacy and safety in a setting that closely mimics human infection and immune responses.

Why Choose Us?

Creative Biolabs leverages NHP models because they offer a unique set of advantages that are critical for de-risking advanced therapeutic pipelines.

Genetic and Immunological Similarities: NHPs share a high degree of genetic and immunological homology with humans, providing the most accurate predictor of how a therapy will behave in the human body.
Clinical Translational Relevance: Data from NHP studies provides essential translational insights, directly informing dose selection, safety margins, and clinical trial design.
Data Types Required for Regulatory Submissions: Regulatory agencies often require comprehensive NHP data, particularly for novel modalities, as a prerequisite for Investigational New Drug (IND) applications.

NHP applications by therapeutic modalities. (Creative Biolabs AI)

Key Applications

NHPs provide a robust platform for evaluating specific aspects of your therapeutic modality.

Vector Biodistribution and Shedding Studies for Gene Therapies: We can precisely track the in vivo distribution and shedding of viral vectors to ensure the therapy is confined to the target tissue and does not spread to other organs or the environment.
Modeling Cytokine Release Syndrome (CRS) for Cell Therapies: By monitoring cytokine levels and clinical signs in NHPs, we can accurately predict and mitigate the risk of CRS, a major safety concern for CAR-T and other cell therapies.
Pharmacokinetic/Pharmacodynamic (PK/PD) and Immunogenicity Studies for Biologics: Our NHP models allow for detailed analysis of a biologic's absorption, distribution, metabolism, and excretion (ADME) profiles, as well as its potential to elicit an unwanted immune response.
Efficacy and Safety Testing for Vaccines: We can evaluate a vaccine's ability to induce a protective immune response and its safety profile in NHP models, which closely mimic human immune function.

How Do Creative Biolabs Support Your Projects?

At Creative Biolabs, we offer a comprehensive suite of services tailored to the specific needs of your therapeutic modality. We provide the right services at the right time to accelerate your program's success. For more information, please contact our team to discuss your project.

Gene Therapy

Explore Services > Cytokine Profiling

Cell Therapy

Explore Services > ADA/Immunogenicity Testing

Biologics & Complex Modalities

Explore Services > Safety & Toxicology

Vaccine & Antiviral

Explore Services > Vaccine Challenge & Protection Studies

Translational Impact

Using NHP models is a strategic investment that provides a high-confidence pathway to the clinic by directly addressing critical translational questions.

More Reliable Early Proof-of-Concept: NHP data provides a clear signal of efficacy in a human-like system, allowing you to confidently move forward with a candidate.
Early Detection of Immune Responses/Toxicity: We can identify potential adverse events, such as cytokine storms or immunogenicity, early in development, enabling timely mitigation strategies.
Reduced Risk of IND Failure: By proactively addressing safety and efficacy concerns, our studies significantly de-risk your program. For example, comprehensive NHP biodistribution data is a direct requirement for most gene therapy IND submissions, which we provide with unmatched precision. This reduces the risk of costly and time-consuming IND failures.

Frequently Asked Questions

Q: What is the resolution and sensitivity of your assays for gene expression analysis in NHPs?

A: Our assays are meticulously developed and validated to meet the highest industry standards. We utilize state-of-the-art technologies that provide exceptional sensitivity for detecting low-level gene expression and a high resolution for differentiating between related sequences. We would be happy to provide detailed validation data for your specific project upon request.

Q: What is the cell source and sample stability for your cell therapy studies?

A: We use primary NHP cells, including peripheral blood mononuclear cells (PBMCs), isolated and processed in our certified facilities. Our standard operating procedures ensure optimal cell viability and sample stability, from collection to downstream analysis. We can work with you to establish a protocol that meets the unique requirements of your therapeutic candidate.

Q: What is the typical turnaround time for data and what format is it provided in?

A: We understand the importance of timely data. Turnaround times vary depending on the complexity of the study, but we work closely with clients to establish a realistic and efficient timeline. Data is provided in a comprehensive, publication-ready format, including raw data files, analyzed results, and a detailed study report.

Q: How do NHP models provide a more reliable prediction of human response compared to other animal models?

A: While rodent and other small animal models are useful for initial screening, NHPs are considered the most predictive preclinical model for humans due to their genetic, physiological, and immunological similarities. This is particularly crucial for complex biologics and immunotherapies, where rodent models often fail to replicate human-specific immune interactions and adverse events.

Q: How do your NHP studies assist with regulatory submissions?

A: Our studies are conducted under strict regulatory guidelines, and the data generated is specifically tailored to meet the requirements of regulatory agencies. This includes comprehensive safety and toxicology reports, PK/PD analysis, and biodistribution data, all of which are critical components of a successful IND application. We are committed to helping you navigate the regulatory landscape with confidence.

Contact Us

Creative Biolabs is your trusted partner for navigating the complex landscape of advanced therapeutic development. Our expertise in NHP applications provides the crucial data and insights you need to confidently advance your program to the clinic. Ready to leverage our NHP services for your next study? Contact Our Team for More Information and to Discuss Your Project.